The Challenge of High Treatment Costs
One of the most significant restraints on the growth of the Anti-VEGF Market is the high cost of the therapies. Branded anti-VEGF drugs are among the most expensive medications on the market, creating a substantial financial burden for patients and healthcare systems. In many countries, the cost can be a barrier to access, particularly for those without robust health insurance or in regions with limited reimbursement policies.
This challenge has led to a greater focus on cost-effectiveness and has accelerated the development of biosimilars and other more affordable alternatives. While new, innovative therapies command premium pricing, the market is gradually shifting towards a model that balances clinical effectiveness with economic viability. This is a critical factor for long-term market growth, especially in a world with rising healthcare costs and an aging population.